VTRS NASDAQ
Viatris Inc.
1W: -4.6%
1M: +13.4%
3M: +3.4%
YTD: +32.1%
1Y: +92.3%
3Y: +104.2%
5Y: +26.0%
$16.65
+0.19 (+1.15%)
Weekly Expected Move ±5.8%
$15
$16
$16
$17
$18
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
3 bullish
0 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (82)
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
Most healthcare companies report higher Y/Y EPS in strong earnings week
RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris (VTRS) Q1 2026 Earnings Transcript
Viatris signals 2026 cash deployment of more than $2.5B while expecting Greater China mid- to high-single-digit growth
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
Viatris rises as Q1 beat indicates growth momentum
Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates
Viatris Non-GAAP EPS of $0.59 beats by $0.09, revenue of $3.51B beats by $150M
Viatris Q1 2026 Earnings Preview: Caution remains around ongoing turnaround
Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS
Viatris Gears Up to Report Q1 Earnings: What's in the Cards?
Stock index futures rise ahead of economic reports
Viatris Announces Chief Financial Officer Transition
Stock index futures mixed as focus remains on U.S.-Iran developments
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Viatris (VTRS) Earnings Expected to Grow: Should You Buy?
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
QSM Asset Management Loads Up 611,000 Mobileye Shares
The 10 Healthcare stocks with the lowest forward P/E ratios
Theravance Stock Declines Around 17% in Three Months: Here's Why
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Insider trades: CrowdStrike, Palo Alto, Lululemon among notable names
Citi's top large-cap stocks with positive ROE trends
Theravance's Q4 Earnings and Revenues Miss Estimates
Viatris sets long-term targets ahead of investor event
Generic drug suppliers could face pressure from Strait of Hormuz closure
Catalyst Watch: Nvidia's GTC Conference, FOMC meeting, Okta event, and triple-witching day
Viatris resolves case over use of woman’s cancer cells to advance drug research
GoodRx to offer up to 85% discount on Viatris drugs
Top 10 healthcare stocks with highest dividend yield amid volatile markets
FDA plans to relax testing rules to encourage biosimilar drugs: report
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
Theravance drops rare disease drug after late-stage trial setback
Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris declares $0.12 dividend
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Viatris forecasts 2026 profit below estimates on India manufacturing woes
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drug pipeline
Viatris, Opus gain as FDA to review label expansion for eyecare drug
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics
Earnings week ahead: NVDA, CRM, HD, BIDU, LOW, DELL, SNOW, AMC, ZM, and more
33 of 52 S&P 500 companies post EPS growth in latest earnings week: Earnings scorecard
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Burney U.S. Factor Rotation ETF Buys Shares of Viatris Inc (NAS:VTRS)
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
Viatris Provides Pipeline Update on Four Regulatory Milestones
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
Viatris to Participate in Upcoming Investor Conferences
Európska štúdia zisťuje klesajúce ceny, rastúce náklady a nedostatky - Viatris a Medicines for Europe prezentujú nezávislú štúdiu počas Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR)
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
Europejskie badanie pokazuje spadające ceny, rosnące koszty i niedobory - wyniki niezależnego badania przedstawione podczas Światowego Tygodnia Wiedzy o Antybiotykach przez firmę Viatris i organizację Medicines for Europe